Result
€36,042 ▼ 93.8%
The result fell in 2025: the 2024 profit included a one-off income of €554,006.
KPL & C°
Lifetime
19 annual accounts with figures on one time axis, 34 filings since 1992peak €658,409 (2024)
€112,592▼ 82.9%
lowest -€35,082 (2023)
€36,042▼ 93.8%
peak €1.4m (2025)
€1.4m▲ 2.7%
€75,809▼ 9.8%
Board3 names since 2022
3 directors and 2 others
Documentsfilings and deeds
02-02-20262 days late
2025micro format
Gross margin from €658,409 to €112,592Result from €577,769 to €36,042Investments €165,327Cash from €94,507 to €39,081
Key points
from the 2025 annual accountsTurnover
≈ €340,000 estimated
The accounts state no turnover.
Investments
€165,327 3.9 × depreciation
Green is investment, beige is depreciation. Land and buildings stand 19.8% higher than in 2024.
Liquidity
40.06 was 25.47 in 2024
Short-term debts fell from €34,965 to €19,850.
Filings
34 annual accounts since 1992
The 2025 accounts came 2 days late. The other nine of the last ten were filed on time.
Position in the sector
94.5%
Higher solvency than 95% of companies in retail trade. Sector median 33.4% · 25,263 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 14,768 companies had the same profile as KPL & C° has now. Each dot stands for 37 companies, two years later.
96.1%
were still trading
3.5%
stopped another way
0.2%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 14,768 companies, not a prediction for KPL & C°. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Chair
Director, since 31-03-2023
Director, since 31-03-2023
- 3 sharesdeed of 06-04-2023
- 2 sharesdeed of 06-04-2023
- 446 sharesdeed of 06-04-2023
Recent changes
Environmental permit granted
Functiewijziging zonder verbouwingswerken · Poperinge
Environmental permit granted
Verbouwen en/of uitbreiden zonder functiewijziging en zonder wijziging van aantal woongelegenheden · Heuvelland
Company renamed from Verschaeve-Grouset& C° to KPL & C°
Changes of role: (director) and (director) · Appointment: (director) · “I) het optreden als tussenpersoon in de dienstverlening; J) het uitbaten van vakantiewoningen en…” (deed in Dutch) · General meeting of 31-03-2023 · Gazette deed
First establishment
VERSCHAEVE-GROUSET & CO CVA, Zevekotestraat 15, Poperinge
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| KPL & C° Poperinge | €1.4m | €112,592 | 94.5% | - |
| SOGIPHARMA Wavre | €1.4m | €114,207 | 34.0% | 0 |
| PHARMALUX Antwerp | €1.4m | €111,636 | 91.4% | 3.5 |
| APOTHEEK ZUIDERKRUIS Antwerp | €1.4m | €110,172 | 11.2% | 1.1 |
| APOTHEEK DE GROOTE Brakel | €1.3m | €120,079 | 93.2% | 1.9 |
| Apotheek Verbanck Westerlo | €1.4m | €130,279 | 85.3% | 1.1 |
| APOTHEEK DE WILDE ZEE Antwerp | €1.5m | €130,936 | 3.6% | 0.9 |
These companies have the same main activity as KPL & C°: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.3m and €1.5m, founded between 1988 and 1992.
Official details
Source: KBO- Status
- Active since 16-04-1991Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 1 other
- Establishment unit
- 2.052.617.7908970 Poperinge, since 30-04-1991
- Financial year end
- 30 June
- Peppol
- Reachable
Insights on KPL & C°
KPL & C° files the micro format. That format states no turnover. The gross margin rose from €102,549 in 2007 to €112,592 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about KPL & C°
- What is the company number of KPL & C°?
- The company number of KPL & C° is 0443.835.673. The VAT number is the same number with BE in front: BE 0443.835.673.
- Where is KPL & C° based?
- The registered office is at Zevekotestraat 15, 8970 Poperinge.Company details
- What does KPL & C° do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of KPL & C°?
- KPL & C° is a private limited company (BV).
- When was KPL & C° founded?
- KPL & C° was founded on 16-04-1991.
- Is KPL & C° still active?
- Yes, KPL & C° is an active enterprise in the KBO register.
- What is the turnover of KPL & C°?
- The turnover in financial year 2025 is ≈ €340,000. This figure is estimated from the gross margin of €112,592 and 31 comparable companies (NACE 477). It probably lies between €240,000 and €640,000.Financials
- Is KPL & C° profitable?
- In financial year 2025, KPL & C° made a profit of €36,042.
- Where can I find the annual accounts of KPL & C°?
- KPL & C° filed 34 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of KPL & C° due?
- KPL & C° must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.